The effect of hydroxyurea on compound heterozygotes for sickle cell-hemoglobin D-Punjab-A single centre experience in eastern India

Pediatric Blood and Cancer

Volumn 61, Issue 8, 2014, Pages 1341-1346

  Patel, Siris ^a   Purohit, Prasanta ^a   Mashon, Ranjeet Singh ^a   Dehury, Snehadhini ^a   Meher, Satyabrata ^a   Sahoo, Sulia ^a   Dash, Subhransu Sekhar ^a   Das, Kishalaya ^a   Das, Padmalaya ^b   Patel, Dilip Kumar ^a  

^a VSS Medical College & Hospital   (India)

^b Asian Institute of Public Health   (India)

Author keywords

HbSD Punjab; Hydroxyurea; Sickle cell anemia; VOC

Indexed keywords

BILIRUBIN; HEMOGLOBIN; HEMOGLOBIN F; HEMOGLOBIN S; HYDROXYUREA; LACTATE DEHYDROGENASE; TOTAL HEMOGLOBIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD TRANSFUSION; CHILD; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DACTYLITIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HETEROZYGOTE; HUMAN; INDIA; LEUKOCYTE; LIVER DYSFUNCTION; LOW DRUG DOSE; MALE; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; NEUTROPHIL COUNT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SICKLE CELL ANEMIA; SICKLE CELL HEMOGLOBIN D PUNJAB; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VASO OCCLUSIVE CRISIS;

HBSD-PUNJAB; HYDROXYUREA; SICKLE CELL ANEMIA; VOC;

ADULT; ANTISICKLING AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBINS, ABNORMAL; HETEROZYGOTE; HUMANS; HYDROXYUREA; INDIA; INFANT; MALE;

EID: 84901976230     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25004     Document Type: Article

References (38)

1. Weatherall DJ, Clegg JB, Kwiatkowski D. The role of genomics in studying genetic susceptibility to infectious disease. Genome Res 1997; 7:967-973.
2. Steinberg MH, Forget BG, Higgs DR, et al. Disorders of hemoglobin. New York: Cambridge University Press; 2001.
3. Weatherall DJ, Clegg JB. Inherited haemoglobin disorders: An increasing global health problem. Bull World Health Organ 2001; 79:704-712.
4. Cawein MJ, Lappat EJ, Brangle RW, et al. Hemoglobin SD disease. Ann Intern Med 1966; 64:62-70.
5. Patel DK, Purohit P, Dehury S, et al. Fetal hemoglobin and alpha thalassemia modulate the phenotypic expression of HbSD-Punjab. Int J Lab Hematol 2013; doi: 10.1111/ijlh.12165. [Epub ahead of print].
6. Adachi K, Kim J, Ballas S, et al. Facilitation of HbS polymerization by the substitution of Glu for Gln at β121. J Biol Chem 1988; 263:5607-5610.
7. Gluckman E. Allogeneic transplantation strategies including haploidentical transplantation in sickle cell disease. Hematology Am Soc Hematol Educ Program 2013; 2013:370-376.
8. Green NS, Ender KL, Pashankar F, et al. Candidate sequence variants, fetal hemoglobin in children with sickle cell disease treated with hydroxyurea. PLoS ONE 2013; 8:e55709.
9. Platt OS, Orkin SH, Dover G, et al. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest 1984; 74:652-656.
10. Ware RE, Aygun B. Advances in the use of hydroxyurea. Hematology Am Soc Hematol Educ Program 2009; 2009:62-69.
11. Lobo CL, Pinto JF, Nascimento EM, et al. The effect of hydroxcarbamide therapy on survival of children with sickle cell disease. Br J Haematol 2013; 161:852-860.
12. Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: Results of a 17-year, single-center trial (LaSHS). Blood 2010; 115:2354-2363.
13. Strouse JJ, Heeney MM. Hydroxyurea for the treatment of sickle cell disease: Efficacy, barriers, toxicity, and management in children. Pediatr Blood Cancer 2012; 59:365-371.
14. Kar BC. Sickle cell disease in India. J Assoc Phys India 1991; 39:954-960.
15. Patel DK, Mashon RS, Patel S, et al. Low dose hydroxyurea is effective in reducing the incidence of painful crisis and frequency of blood transfusion in sickle cell anemia patients from eastern India. Hemoglobin 2012; 36:409-420.
16. Patel DK. Clinical aspects of sickle cell disease in India. 5th Brazilian Symposium for Sickle cell disease and other hemoglobinopathies. Belo Horizonte, Brazil; 2009. Available from: http://www.cehmob.org.br/simposio/html/english/download.html
17. Braga LB, Ferriira AC, Guimaraes M. Clinical and laboratory effects of hydroxyurea in children and adolescents with sickle cell anemia: A Portugese hospital study. Hemoglobin 2005; 29:171-180.
18. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995; 332:1317-1322.
19. Charache S, Terrin ML, Moore RD, et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea. Control Clin Trials 1995; 16:432-446.
20. Wu DY, Ugozzoli L, Pal BK, et al. Allele-specific enzymatic amplification of β-globin genomic DNA for diagnosis of sickle cell anemia. Proc Natl Acad Sci USA 1989; 86:2757-2760.
21. Old JM. Screening and genetic diagnosis of haemoglobin disorders. Blood Rev 2003; 17:43-53.
22. Patel DK, Mashon RS, Patel S, et al. β-globin gene haplotypes linked with the Hb D-Punjab [β121(GH4)Glu→Gln. GAA > CAA] mutation in eastern India. Hemoglobin 2010; 34:530-537.
23. Perea FJ, Casas-Castaneda M, Villalobos-Arambula AR, et al. Hb D-Los Angeles associated with Hb S or β-thalassemia in four Mexican Mestizo families. Hemoglobin 1999; 23:231-237.
24. Yavarian M, Karimi M, Paran F, et al. Multi centric origin of Hb D-Punjab [b121(GH4)Glu→Gln. GAA > CAA]. Hemoglobin 2009; 33:399-405.
25. Oberoi S, Das R, Trehan A, et al. HbSD-Punjab: Clinical and hematological profile of a rare hemoglobinopathy. J Pediatr Hematol Oncol 2013; [Epub ahead of print].
26. Mabaera R, West RJ, Conine SJ, et al. A cell stress signaling model of fetal hemoglobin induction; what doesn't kill red blood cells makes them stronger. Exp Hematol 2008; 36:1057-1072.
27. Steinberg MH, Lu Z-H, Barton FB, et al. Fetal hemoglobin in sickle cell anemia: Determinants of response to hydroxyurea. Blood 1997; 89:1078-1088.
28. Adragna NC, Fonseca P, Lauf PK. Hydroxyurea affects cell morphology, cation transport, and red blood cell adhesion in cultured vascular endothelial cells. Blood 1994; 83:553-556.
29. Bridges KR, Barabino GD, Brugnara MR, et al. A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy. Blood 1996; 88:4701-4710.
30. Styles LA, Lubin B, Vichinsky E, et al. Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea. Blood 1997; 89:2554-2559.
31. McGann PT, Flanagan JM, Howard TA, et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: Results from the BABY-HUG phase III clinical trial. Pediatr Blood Cancer 2012; 59:254-257.
32. Friedrisch JR, Pra D, Maluf SW, et al. DNA damage in blood leukocytes of individuals with sickle cell disease treated with hydroxyurea. Mutat Res 2008; 649:213-220.
33. da Silva Rocha LB, Dias Elias DB, Barbosa MC, et al. DNA damage in leukocytes of sickle cell anemia patients is associated with hydroxyurea therapy and with HBB*S haplotype. Mutat Res 2012; 749:48-52.
34. Grigg A, Effect of hydroxyurea on sperm count motility morphology in adult men with sickle cell or myeloproliferative disease. Intern Med J 2007; 37:190-192.
35. Berthaut I, Guignedoux G, Kirsch-Noir F, et al. Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. Haematologica 2008; 93:988-993.
36. Charache S, Dover GJ, Moore RD, et al. Hydroxyurea: Effects on hemoglobin F production in patients with sickle cell anemia. Blood 1992; 79:2555-2565.
37. Kinney TR, Helms RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, a phase I/II trial. Blood 1999; 94:1550-1554.
38. Ware RE, Eggleston B, Redding-Lallinger R, et al. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood 2002; 99:10-14.